Andrea Foli

Andrea Foli

Auto-generated profile, based on publicly available information

Andrea Foli

Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, ITA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2012 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
Giovanni PalladiniGiovanni Palladini
Giovanni Palladini
AFAndrea Foli
Andrea Foli
PMPaolo Milani
Paolo Milani
Paola RussoPaola Russo
Paola Russo
RARiccardo Albertini
Riccardo Albertini
GMGiampaolo Merlini
Giampaolo Merlini
In AL amyloidosis prognosis depends on the severity of heart dysfunction which is best assessed by natriuretic peptides (BNP and NT‐proBNP). However, their clearance relies on glomerular filtration rate (GFR) and their concentration increases with renal failure. We evaluated the diagnostic and prognostic performance of NT‐proBNP and BNP in 248 patients with AL amyloidosis with different degrees of renal failure. Patients were grouped according to GFR. Group 1 comprised 109 patients with GFR ≥60 mL/min/1.73 m2, Group 2, 77 subjects with GFR <60 and ≥15 mL/min/1.73 m2, and Group 3, 62 patients with GFR <15 mL/min/1.73 m2. The ability of natriuretic peptides to detect heart involvement and to predict survival in the three groups was assessed. Decreasing eGFR required higher cutoffs of both NT‐proBNP and BNP for detecting heart involvement and predicting survival. Both natriuretic peptides were independent prognostic markers in Groups 1 and 2, whereas in Group 3 only BNP independently predicted survival. Natriuretic peptides are powerful and useful markers of cardiac dysfunction and prognosis, provided that eGFR is considered in interpreting their clinical meaning. BNP should be preferred in patients with end‐stage renal failure. Am. J. Hematol. 87:465–471, 2012.

6 April 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
PMPaolo Milani
Paolo Milani
MBMarco Basset
Marco Basset
PCPaola Curci
Paola Curci
AFAndrea Foli
Andrea Foli
RRRita Rizzi
Rita Rizzi
Giovanni PalladiniGiovanni Palladini
Giovanni Palladini
Key Points: Daratumumab is effective in treated light chain deposition disease. Daratumumab can prevent progression of renal failure in these patients.

23 August 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
PCPasquale Cascino
Pasquale Cascino
ANAlice Nevone
Alice Nevone
MPMaggie Piscitelli
Maggie Piscitelli
CSClaudia Scopelliti
Claudia Scopelliti
MGMaria Girelli
Maria Girelli
MNMario Nuvolone
Mario Nuvolone

4 September 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
MBMarco Basset
Marco Basset
PMPaolo Milani
Paolo Milani
MNMario Nuvolone
Mario Nuvolone
FBFrancesca Benigna
Francesca Benigna
LRLara Rodigari
Lara Rodigari
Giovanni PalladiniGiovanni Palladini
Giovanni Palladini
Autologous stem cell transplant (ASCT) is highly effective in selected patients with light chain (AL) amyloidosis. Bortezomib, preceding or following ASCT, improves responses. Satisfactory responses, including at least a partial response, very good partial response (VGPR) with organ response, or complete response, can be observed after induction therapy alone. We report 139 patients treated upfront with cyclophosphamide/bortezomib/dexamethasone (CyBorD), followed by ASCT only if response was unsatisfactory. Only 1 treatment-related death was observed. After CyBorD, hematologic response (HR) rate was 68% (VGPR or better, 51%), with 45% satisfactory responses. Transplant was performed in 55 (40%) subjects and resulted in an 80% HR rate (65% ≥ VGPR). Five-year survival was 86% and 84% in patients treated with ASCT or CyBorD alone, respectively (P = .438). Also, 6- and 12- month landmark analyses did not show differences in survival. Duration of response was not different in the 2 groups (60 vs 49 months; P = .670). Twenty-one (15%) patients with an unsatisfactory response to CyBorD could not undergo ASCT because of ineligibility or refusal; instead, they received rescue chemotherapy, with HR in 38% of cases and 51% 5-year survival. This sequential response-driven approach, offering ASCT to patients who do not attain satisfactory response to upfront CyBorD, is very safe and effective in AL amyloidosis.

9 November 2011 in Amyloid
Verified
Journal Article
Closed access
PDF file
Giovanni PalladiniGiovanni Palladini
Giovanni Palladini
ABAlessandra Barassi
Alessandra Barassi
Stefano PerliniStefano Perlini
Stefano Perlini
PMPaolo Milani
Paolo Milani
AFAndrea Foli
Andrea Foli
GMGiampaolo Merlini
Giampaolo Merlini
Background: Cardiac biomarkers play a major role in the identification of patients at risk of early death in AL amyloidosis, and a staging system based on amino-terminal pro-natriuretic peptide type-B (NT-proBNP) and troponins (cTn) is used for prognostic stratification. Adrenomedullin is produced by several tissues including the heart, and portends a poor prognosis in heart diseases. We investigated the ability of midregional proadrenomedullin (MR-proADM) to predict early death in AL amyloidosis. Methods: One-hundred and thirty consecutive patients with newly-diagnosed AL amyloidosis were prospectively enrolled. The impact on survival of NT-proBNP, cTnI and MR-proADM was evaluated. Results: The concentration of MR-proADM correlated with systolic and diastolic function, but did not reflect the amount of amyloid deposited in the heart. Moreover, MR-proADM was associated with non-cardiac markers of advanced disease. The staging system based on NT-proBNP and cTnI identified high-risk subjects, but could not discriminate good-risk and intermediate-risk patients. Conversely, a staging system based on MR-proADM and cTnI identified 3 groups with significantly different survivals. Conclusions: Midregional-proADM is a powerful prognostic marker in AL amyloidosis, which may not only reflect cardiac dysfunction but also widespread systemic disease, and can be combined with cTn for detecting patients at risk of early death.

3 November 2022 in Blood
Verified
Journal Article
Closed access
PDF file
MBMarco Basset
Marco Basset
PMPaolo Milani
Paolo Milani
AFAndrea Foli
Andrea Foli
MNMario Nuvolone
Mario Nuvolone
PBPietro Benvenuti
Pietro Benvenuti
Giovanni PalladiniGiovanni Palladini
Giovanni Palladini
Patients with immunoglobulin light chain (AL) amyloidosis and stage IIIb cardiac involvement have a dismal outcome despite the introduction of novel treatments. However, a rapid hematologic response translates in better survival. We evaluated the impact of early cardiac response and its depth on outcome in 249 patients with newly diagnosed stage IIIb cardiac AL amyloidosis. Hematologic and cardiac responses were evaluated by intent to treat. After a median follow-up of 52 months, 219 (84%) patients died, and median survival was 4.2 months. The 30- and 90-day hematologic response rates were 22% (at least very good partial response [VGPR] in 9%) and 24% (at least VGPR in 15%), respectively. Early hematologic response resulted in better survival. At 90 days, 21 (8%) patients achieved a cardiac response (cardiac very good partial response [cardiac VGPR] in 12 cases and cardiac partial response [cardiac PR] in 9). At the 90-day landmark analysis, cardiac response resulted in longer survival (median, 54 months), also in those patients who have achieved at least VGPR (median, 62 vs 26 months, P = .011). Patients with cardiac VGPR had a longer survival than those with cardiac PR (median, 92 vs 24 months; P = .027), whereas patients without cardiac response had a poor survival (median, 6 months). A baseline difference of involved/uninvolved free light chains > 50 mg/L (odds ratio [OR], 0.21, P = .024) and a bone marrow plasma cell infiltrate > 10% (OR, 0.23, P = .040) were negative predictors of 90-day cardiac response. Early cardiac responses are rare but possible in stage IIIb AL amyloidosis and translate to longer survival.